Boštjan Šeruga

university of ljubljana

H指数:39

被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Importance of genetic testing in childhood cancer survivors for hereditary cancer predisposition syndromes

儿童癌症幸存者进行遗传癌症易感综合征基因检测的重要性

Hereditary Cancer in Clinical Practice

IF2.4

2026-04-150

PRE

A safety and survival analysis of sequential systemic anticancer treatment in patients with end-stage kidney disease and metastatic renal cell carcinoma

晚期肾病患者和转移性肾细胞癌患者序贯系统性抗肿瘤治疗的安全性与生存分析

Nephrology Dialysis Transplantation

IF5.6

2025-10-010

A safety and survival analysis of sequential systemic anticancer treatment in patients with end-stage kidney disease and metastatic renal cell carcinoma

终末期肾病合并转移性肾细胞癌患者序贯系统性抗肿瘤治疗的安全性与生存分析

Nephrology Dialysis Transplantation

IF5.6

2025-10-010

PRE

The Effect of Staging Intervals on Progression-Free Survival in Registration Studies of Oncologic Drugs: A Meta-Analysis

肿瘤药物注册研究中分期间隔对无进展生存期的影响：一项荟萃分析

CANCERS

IF4.4

2025-04-180

Challenges in the management of operable triple-negative breast cancer in a survivor of the B-cell acute lymphoblastic leukemia: a case report

B细胞急性淋巴细胞白血病幸存者中可操作的三阴性乳腺癌的管理挑战: 病例报告

FRONTIERS IN ONCOLOGY

IF3.3

2024-05-160

OAAI

Aggressive anticancer treatment in the last 2 weeks of life

ESMO OPEN

IF8.3

2024-03-011

OAAI

Association of androgen receptor and tumour-infiltrating lymphocytes with bone recurrence in triple-negative breast cancer

雄激素受体和肿瘤浸润淋巴细胞与三阴性乳腺癌骨复发的关系

JOURNAL OF BONE ONCOLOGY

IF3.5

2024-02-011

OAAI

Feasibility of mutation detection in cytological samples from metastasis in patients with metastatic prostate cancer

ANNALS OF ONCOLOGY

IF65.4

2023-10-010

The trajectory of sarcopenia following diagnosis of prostate cancer: A systematic review and meta-analysis

前列腺癌诊断后肌肉减少的轨迹: 系统回顾和荟萃分析

JOURNAL OF GERIATRIC ONCOLOGY

IF2.7

2023-09-014

Prognostic Impact of Nutritional Status on Overall Survival and Health-Related Quality of Life in Men with Advanced Prostate Cancer

NUTRIENTS

IF5

2023-02-203

OAAI

The impact of de-escalation of adjuvant systemic therapy on the outcome of women with early ER+/HER2+breast cancer

ANNALS OF ONCOLOGY

IF65.4

2021-09-010

OAAI

Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade

过去十年在实体瘤的3期随机对照试验中研究的药物的疗效，安全性和耐受性

SCIENTIFIC REPORTS

IF3.9

2021-05-251

OAAI

Clinical benefit of cancer drugs approved in Switzerland during the last decade

ANNALS OF ONCOLOGY

IF65.4

2020-09-010

OAAI

Prognostic role of nutritional status (NS) for health-related quality of life (HRQoL) in men with advanced prostate cancer

ANNALS OF ONCOLOGY

IF65.4

2020-09-012

OAAI

Medical Oncology Workload in Europe: One Continent, Several Worlds

欧洲的医学肿瘤学工作量: 一个大陆，几个世界

CLINICAL ONCOLOGY

IF3

2020-01-0115

OAAI

Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis

局限性肾癌根治术后辅助放射治疗的系统评价和Meta分析

EUROPEAN UROLOGY ONCOLOGY

IF9.3

2019-07-0110

PREAI

Cancer care workforce in Africa: perspectives from a global survey

INFECTIOUS AGENTS AND CANCER

IF2.8

2019-05-2144

OAAI

Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials

MAYO CLINIC PROCEEDINGS

IF6.7

2019-01-019

PREAI

Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis

CLINICAL ONCOLOGY

IF3

2018-04-0137

PREAI

Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis

BREAST CANCER RESEARCH AND TREATMENT

IF3

2018-02-0812

PREAI

Boštjan Šeruga

个人简介

教育背景

工作经历

荣誉奖项

研究方向